Drug Pricing: A Game Of Chutes & Ladders
Executive Summary
The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for industry – but there have been a few setbacks and more may come.
You may also be interested in...
Medicare Part D Drug Rebate Rule Finally Sees Light Of Day: Now What?
Assurances from HHS Secretary Azar that rule will not significantly raise premiums and federal spending amount to a request to ‘just trust me.’
Drug Price Transparency Rule Tees Up Constitutional Concerns
Trump Administration addresses concerns that the rule violates the First Amendment and exceeds its statutory authority in the final rule, which is strongly opposed by biopharma.
COVID Vaccines Getting Parallel Review: ACIP To Begin Process Before FDA Decisions
With goal of distributing vaccines within 24 hours of emergency use authorization, HHS is hoping to convene CDC's ACIP concurrent with the FDA review, Alex Azar says.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports